Thermal imaging developer Computerized Thermal Imaging has submitted the fifth and final module of its premarket approval (PMA) application to the Food and Drug Administration for its Breast Cancer System 2100. Lake Oswego, OR-based CTI is seeking FDA clearance for the unit as an adjunct to mammography and clinical examination. Breast Cancer System 2100 uses thermal imaging to help doctors differentiate between benign and malignant breast lesions, according to CTI.
By AuntMinnie.com staff writersJune 18, 2001
Related Reading
CTI adds six distributors, May 24, 2001
Packer retires as CTI's president/COO, March 12, 2001
Copyright © 2001 AuntMinnie.com
